Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Virology
Published in: Archives of Virology 4/2018

01-04-2018 | Original Article

IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo

Authors: Shadi Khodamoradi, Mohammad Shenagari, Masoumeh Tavasoti Kheiri, Farzaneh Sabahi, Abbas Jamali, Ahmad Heidari, Babak Ashrafkhani

Published in: Archives of Virology | Issue 4/2018

Login to get access

Abstract

Vaccination is the most effective method for the prevention of influenza virus infection. Currently used influenza vaccines that target the highly polymorphic viral surface antigens can provide protection when well matched with circulating virus strains. Antigenic drift or cyclically occurring pandemics may hamper the efficacy of these vaccines, which are chosen prior to each flu season. Therefore, a universal vaccine, designed to induce broadly cross-protective immunity against the highly conserved internal antigens M1 and nucleoprotein could provide durable protection against various influenza virus subtypes, and it could also reduce the impact of pandemic influenza, which occurs less frequently. Here, we describe a new influenza vaccine candidate in which two highly conserved antigens, nucleoprotein (NP) and matrix (M1), are simultaneously expressed from a bicistronic vector termed pIRESM1/NP. Mice were immunized intradermally four times with the pIRESM1/NP construct. The protection efficacy of the gene-based vaccine was assessed by IFN-γ and Granzyme B ELISpot assays, follow-up observation of weight loss, and survival rates of the mice groups against lethal challenges with influenza A virus subtypes H1N1 and H5N1. The group that received pIRESM1/NP showed full protection against disease following lethal challenge with H1N1 and H5N1. This group also generated significantly higher host immune cellular responses than the other groups. These results demonstrate that a DNA vaccine strategy based on co-expression of the M1 and NP proteins could provide an effective way to control influenza virus infection.
Literature
1.
Debbie B, Schumacher J (2004) The virus and the vaccine. Macmillan, New York (ISBN 0-312-34272-1)
2.
Peiris JS, de Jong MD, Guan Y (2007) Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 20:243–267PubMedPubMedCentral
3.
Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus AD, Fouchier RA (2004) Mapping the antigenic and genetic evolution of influenza virus. Science 305(5682):371–376PubMed
4.
Wong SS, Webby RJ (2013) Traditional and new influenza vaccines. Clin Microbiol 26:476–492
5.
Palese P, Shaw ML (2009) Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM (ed) Fields virology, vol 2, 5th edn. Lippicott Williams and Wilkins, Philadelphia, pp 1647–1690
6.
Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, Brusic V et al (2007) Evolutionarily conserved protein sequences of influenza A viruses, avian and human, as vaccine targets. PLoS One 2:e1190PubMedPubMedCentral
7.
Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF (2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82:5161–5166PubMedPubMedCentral
8.
Lee LY, Ha LA, Simmons C, de Jong MD, Chau NV, Schumacher R et al (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118:3478–3490PubMedPubMedCentral
9.
Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K et al (2001) Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 19:3681–3691PubMed
10.
Chen Q, Kuang H, Wang H, Fang F, Yang Z, Zhang Z et al (2009) Comparing the ability of a series of viral proteinexpressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes 38:30–38PubMed
11.
Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT (2002) Vaccination of pigs with a DNA construct expressing an influenza virus M2–nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 83:1851–1859PubMed
12.
Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z et al (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13:426–435PubMedPubMedCentral
13.
Wraith DC, Vessey AE, Askonas BA (1987) Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol 68:433–440PubMed
14.
Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, Nakajima K et al (1996) Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol 156:3892–3900PubMed
15.
Wang W, Huang B, Jiang T, Wang X, Qi X, Gao Y et al (2012) Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli. PLoS One 7:e52488PubMedPubMedCentral
16.
Roose K, Fiers W, Saelens X (2009) Pandemic preparedness: toward a universal influenza vaccine. Drug News Perspect 22:80–92PubMed
17.
Lo CY, Wu Z, Misplon JA, Price GE, Pappas C, Kong WP et al (2008) Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine 26:2062–2072PubMed
18.
Kheiri MT, Jamali A, Shenagari M, Hashemi H, Sabahi F, Atyabi F et al (2012) Influenza virosome/DNA vaccine complex as a new formulation to induce intra-subtypic protection against influenza virus challenge. Antivir Res 95:229–236PubMed
19.
Krammer F, Palese P, Steel J (2015) Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol 386:301–321PubMed
20.
Wang W, Li R, Deng Y, Lu N, Chen H, Meng X et al (2015) Protective efficacy of the conserved NP, PB1, and M1 proteins as immunogens in DNA- and vaccinia virus-based universal influenza A virus vaccines in mice. Clin Vaccine Immunol 22(6):618–630PubMedPubMedCentral
21.
22.
He F, Leyrer S, Kwang J (2016) Strategies towards universal pandemic influenza vaccines. Expert Rev Vaccines 15(2):215–225PubMed
23.
Rudenko L, van den Bosch H, Kiseleva I, Mironov A, Naikhin A, Larionova N et al (2011) Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 29(1):A40–A44PubMed
24.
Ulmer JB, Deck RR, de Witt CM, Friedman A, Donnelly JJ, Liu MA (1994) Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 12:1541–1544PubMed
25.
Rudenko L, Isakova-Sivak I, Naykhin A, Kiseleva I, Stukova M, Erofeeva M et al (2016) H7N9 live attenuated influenza vaccine in healthy adults: a randomized, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis 16(3):303–310PubMed
26.
de Jonge J, Isakova-Sivak I, van Dijken H, Spijkers S, Mouthaan J, de Jong R et al (2016) H7N9 live attenuated influenza vaccine is highly immunogenic, prevents virus replication, and protects against severe bronchopneumonia in ferrets. Mol Ther 24(5):991–1002PubMedPubMedCentral
27.
Rekstin A, Isakova-Sivak I, Petukhova G, Korenkov D, Losev I, Smolonogina T et al (2017) Immunogenicity and cross protection in mice afforded by pandemic H1N1 live attenuated influenza vaccine containing wild-type nucleoprotein. Biomed Res Int 2017:9359276PubMedPubMedCentral
28.
Baz M, Luke CJ, Cheng X, Jin H, Subbarao K (2013) H5N1 vaccines in humans. Virus Res 178:78–98PubMed
29.
Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ et al (2012) Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 55:19–25PubMedPubMedCentral
30.
Xu K, Ling ZY, Sun L, Xu Y, Bian C, He Y et al (2011) Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus. Viral Immunol 24:45–56PubMedPubMedCentral
31.
Boyd AC, Ruiz-Hernandez R, Peroval MY, Carson C, Balkissoon D, Staines K et al (2013) Towards a universal vaccine for avian influenza: protective efficacy of modified vaccinia virus ankara and adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus. Vaccine 31:670–675PubMedPubMedCentral
32.
Pandey A, Singh N, Vemula SV, Couetil L, Katz JM, Donis R et al (2012) Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS One 7:e33428PubMedPubMedCentral
33.
Li Z, Gabbard JD, Mooney A, Chen Z, Tompkins SM, He B (2013) Efficacy of parainfluenza virus 5 mutants expressing hemagglutinin from H5N1 influenza A virus in mice. J Virol 87:9604–9609PubMedPubMedCentral
34.
Zhou D, Wu TL, Lasaro MO, Latimer BP, Parzych EM, Bian A et al (2010) A universal influenza a vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol Ther 18:2182–2189PubMedPubMedCentral
35.
Donnelly JJ, Friedman A, Ulmer JB, Liu MA (1997) Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 15:865–868PubMed
36.
Jeon SH, Ben-Yedidia T, Arnon R (2002) Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine 20:2772–2780PubMed
37.
Shen Y, Muramatsu SI, Ikeguchi K, Fujimoto KI, Fan DS, Ogawa M et al (2000) Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson’s disease. Hum Gene Ther 11:1509–1519PubMed
38.
Zhang W, Li W, Li Y, Li H, Wang B, Wang F et al (2009) Immune effects against influenza A virus and a novel DNA vaccine with co-expression of haemagglutinin- and neuraminidase-encoding genes. J Med Microbiol 58:845–854PubMed
39.
Brown DM, Dilzer AM, Meents DL, Swain SL (2006) CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 177:2888–2898PubMed
40.
Koopman G, Mortier D, Hofman S, Mathy N, Koutsoukos M, Ertl P et al (2008) Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J Gen Virol 89:540–553PubMed
41.
Ewen CL, Rong J, Kokaji AI, Bleackley RC, Kane KP (2006) Evaluating antigen-specific cytotoxic T lymphocyte responses by a novel mouse granzyme B ELISPOT assay. J Immunol Methods 308:156–166PubMed
42.
Di Mario G, Sciaraffia E, Facchini M, Gubinelli F, Soprana E, Panigada M, Bernasconi V, Garulli B, Siccardi A, Donatelli I, Castrucci MR (2017) Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins. Pathog Glob Health 12:1–7
43.
Gschoesser C, Almanzar G, Hainz U, Ortin J, Schonitzer D, Schild H, Saurwein-Teissl M, Grubeck-Loebenstein B (2002) CD4+ and CD8+ mediated cellular immune response to recombinant influenza nucleoprotein. Vaccine 20:3731–3738PubMed
44.
Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A (2007) Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci USA 104:246–251PubMed
45.
Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, Renshaw M, Sambhara S, Katz JM (2002) DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8:796–801PubMedPubMedCentral
46.
Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL (2009) Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27:6512–6521PubMed
47.
Thomas PG, Keating R, Hulse-Post DJ, Doherty PC (2006) Cell-mediated protection in influenza infection. Emerg Infect Dis 12:48–54PubMedPubMedCentral
48.
de Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X (2008) An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 283:11382–11387PubMedPubMedCentral
49.
O’Hagan DT, de Gregorio E (2009) The path to a successful vaccine adjuvant—‘the long and winding road’. Drug Discov Today 14:541–551PubMed
50.
Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, Hill AV, Gilbert SC (2014) Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther 22:233–238PubMed
51.
Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, Ladell K, Lambe T, Milicic A, Price DA, Hill AV, Gilbert SC (2012) A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One 7:e48322PubMedPubMedCentral
52.
53.
Ellebedy AH, Webby RJ (2009) Influenza vaccines. Vaccine 27:65–68
54.
Kaiser J (2006) A one-size-fits-all flu vaccine? Science 312:380–382PubMed
55.
Sui Z, Chen Q, Fang F, Zheng M, Chen Z (2010) Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant. Vaccine 28:7690–7698PubMed
56.
Zheng M, Luo J, Chen Z (2014) Development of universal influenza vaccines based on influenza virus M and NP genes. Infection 42:251–262PubMed
Metadata
Title
IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo
Authors
Shadi Khodamoradi
Mohammad Shenagari
Masoumeh Tavasoti Kheiri
Farzaneh Sabahi
Abbas Jamali
Ahmad Heidari
Babak Ashrafkhani
Publication date
01-04-2018
Publisher
Springer Vienna
Published in
Archives of Virology / Issue 4/2018
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-017-3682-9

Other articles of this Issue 4/2018

Archives of Virology 4/2018 Go to the issue

Original Article

Distribution of IL28B and IL10 polymorphisms as genetic predictors of treatment response in Pakistani HCV genotype 3 patients

Original Article

Identification and genetic characterization of polyomaviruses in estrildid and fringillid finches

Brief Report

A novel passerivirus (family Picornaviridae) in an outbreak of enteritis with high mortality in estrildid finches (Uraeginthus sp.)

Review

Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review

Virology Division News

Recognition of six additional cystoviruses: Pseudomonas virus phi6 is no longer the sole species of the family Cystoviridae

Annotated Sequence Record

Complete genome sequence of a phage hyperparasite of Candidatus Xenohaliotis californiensis (Rickettsiales) – a pathogen of Haliotis spp (Gasteropoda)
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits